Cidel Asset Management Inc. Trims Stock Position in Zoetis Inc. $ZTS

Cidel Asset Management Inc. trimmed its position in Zoetis Inc. (NYSE:ZTS) by 13.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 101,862 shares of the company’s stock after selling 16,513 shares during the quarter. Cidel Asset Management Inc.’s holdings in Zoetis were worth $12,816,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in ZTS. CIBC Asset Management Inc raised its stake in shares of Zoetis by 4.3% in the 3rd quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock valued at $36,745,000 after acquiring an additional 10,434 shares during the period. Mitsubishi UFJ Trust & Banking Corp boosted its position in shares of Zoetis by 6.5% during the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock worth $43,235,000 after buying an additional 18,040 shares during the period. Nordea Investment Management AB boosted its holdings in Zoetis by 79.2% during the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after acquiring an additional 2,179,578 shares during the period. Ninety One UK Ltd lifted its position in shares of Zoetis by 19.6% during the third quarter. Ninety One UK Ltd now owns 1,119,132 shares of the company’s stock worth $163,751,000 after purchasing an additional 183,686 shares in the last quarter. Finally, Quilter Plc boosted its stake in shares of Zoetis by 10.2% in the third quarter. Quilter Plc now owns 438,959 shares of the company’s stock valued at $64,228,000 after purchasing an additional 40,615 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of NYSE ZTS opened at $117.83 on Monday. The stock’s 50-day simple moving average is $122.71 and its 200-day simple moving average is $127.96. The firm has a market capitalization of $49.74 billion, a PE ratio of 19.57, a price-to-earnings-growth ratio of 1.80 and a beta of 0.98. Zoetis Inc. has a fifty-two week low of $113.29 and a fifty-two week high of $172.23. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same period in the prior year, the firm posted $1.40 earnings per share. The firm’s revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. Zoetis’s dividend payout ratio is 35.22%.

Wall Street Analyst Weigh In

ZTS has been the subject of a number of research reports. UBS Group set a $136.00 price objective on shares of Zoetis in a report on Thursday, January 29th. Barclays initiated coverage on shares of Zoetis in a research note on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price target for the company. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Piper Sandler reiterated a “neutral” rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Finally, Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Six research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.